Sotorasib is more cost-effective in treating patients with KRAS G12C non–small cell lung cancer (NSCLC) compared with adagrasib in second- and subsequent-line treatment, according to a new study.1 This result can help clinicians choose the most appropriate treatment for their...
Health KRAS Lung Cancer: New Drug Beats Resistance by Dr. Priya Deshmukh - Senior Editor, Health January 2, 2026 by Dr. Priya Deshmukh - Senior Editor, Health January 2, 2026 Beyond KRAS Inhibitors: ‘Molecular Glue’ Offers New Hope for Lung...
Health KRAS-Mutant Lung Cancer: New Drug Fights Resistance by Grace Chen January 2, 2026 written by Grace Chen January 2, 2026 Molecular Glue Approach Shows promise in Combating KRAS-Mutant Lung Cancer A novel strategy combining a “molecular glue” with existing...
For years, KRAS-mutant non-small cell lung cancer (NSCLC) has presented a formidable challenge too oncologists. These cancers often prove resistant to treatment, leaving patients with limited options and a frustratingly short window of success. Though, groundbreaking research is offering a...
Health KRAS-Mutant Lung Cancer: New Drug Overcomes Resistance by archynetyscom December 31, 2025 December 31, 2025 University of Michigan researchers reveal a promising approach for hard-to-treat lung cancers that combines a molecular glue with KRAS inhibitors to delay resistance-leading to...
Health KRAS Lung Cancer Drug: Overcoming Resistance by Dr. Jennifer Chen December 31, 2025 written by Dr. Jennifer Chen December 31, 2025 Summary of the Article: New Drug Combination Shows Promise Against KRAS-Mutant Lung Cancer This article discusses a new...
University of Michigan researchers reveal a promising approach for hard-to-treat lung cancers that combines a molecular glue with KRAS inhibitors to delay resistance-leading to dramatic tumor shrinkage in lab models. Lung cancer remains the leading cause of cancer death in...
